A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood cancer journal (New York) 2019-07, Vol.9 (8), p.58-5, Article 58
Hauptverfasser:	Spencer, Andrew, Walker, Patricia, Asvadi, Parisa, Campbell, Douglas H., Reed, Kate, Herbert, Ben R., Breen, Edmond J., Copeman, Michael C., Dunn, Rosanne D.
Format:	Artikel
Sprache:	eng
Schlagworte:	13/1 13/21 59/78 631/250/249/1623 631/67/1059/2325 631/67/1990/804 631/67/327 Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacokinetics Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - pharmacokinetics Biomedical and Life Sciences Biomedicine Cancer Research Correspondence Dose-Response Relationship, Drug Hematology Humans Immunoglobulin kappa-Chains - immunology Middle Aged Monoclonal antibodies Multiple Myeloma - drug therapy Multiple Myeloma - immunology Multiple Myeloma - microbiology Multiple Myeloma - pathology Oncology Prognosis Tissue Distribution
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!